Amgen (HKSE:04332) Cyclically Adjusted FCF per Share: HK$95.53 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:04332 Amgen Inc HKSE:04332
86 GF Score
Price HK$1,761.00
GF Value HK$1,707.80
! 5 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted FCF per Share?

Amgen HKSE:04332 86 Cyclically Adjusted FCF per Share is HK$95.53 as of Jun. 2026. GuruFocus rates HKSE:04332 with a GF Score™ of 86/100 and a GF Value™ of HK$1,707.80. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Amgen's adjusted free cash flow per share for the three months ended in Jun. 2026 was HK$50.268. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is HK$95.53 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Amgen's average Cyclically Adjusted FCF Growth Rate was 5.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Amgen was 25.30% per year. The lowest was 4.70% per year. And the median was 15.20% per year.

As of today (2026-09-14), Amgen's current stock price is HK$1761.00. Amgen's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was HK$95.53. Amgen's Cyclically Adjusted Price-to-FCF of today is 18.43.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 24.24. The lowest was 13.20. And the median was 18.59.


Amgen  (HKSE:04332) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Amgen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=1761.00/95.53
=18.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 24.24. The lowest was 13.20. And the median was 18.59.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Amgen Cyclically Adjusted FCF per Share Related Terms


Amgen Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted FCF per Share Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 115.04 110.45 106.75 125.28 101.68

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 117.87 119.25 101.68 96.17 95.53

HKSE:04332 vs GILD, PFE, BMY: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted Price-to-FCF falls into.


HKSE:04332
86GF Score
Amgen Inc HKSE:04332
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=50.268/333.9520*333.9520
=50.268

Current CPI (Jun. 2026) = 333.9520.

Amgen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 26.720 241.428 36.960
201612 30.041 241.432 41.553
201703 23.235 243.801 31.827
201706 22.624 244.955 30.844
201709 35.131 246.819 47.533
201712 30.767 246.524 41.678
201803 28.365 249.554 37.958
201806 22.768 251.989 30.174
201809 37.455 252.439 49.549
201812 36.218 251.233 48.143
201903 21.679 254.202 28.480
201906 16.293 256.143 21.242
201909 41.739 256.759 54.288
201912 30.407 256.974 39.516
202003 26.041 258.115 33.692
202006 35.137 257.797 45.517
202009 42.539 260.280 54.580
202012 26.282 260.474 33.696
202103 25.901 264.877 32.655
202106 23.528 271.696 28.919
202109 29.703 274.310 36.161
202112 34.860 278.802 41.756
202203 28.026 287.504 32.554
202206 24.611 296.311 27.737
202209 41.115 296.808 46.260
202212 33.414 296.797 37.597
202303 10.504 301.836 11.622
202306 55.983 305.109 61.275
202309 36.552 307.789 39.659
202312 4.195 306.746 4.567
202403 6.699 312.332 7.163
202406 32.063 314.175 34.081
202409 47.637 315.301 50.455
202412 63.222 315.605 66.897
202503 14.080 319.799 14.703
202506 27.724 322.561 28.703
202509 61.014 324.800 62.733
202512 13.796 324.054 14.217
202603 21.250 330.213 21.491
202606 50.268 333.952 50.268

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of HK$95.53 mean?
Amgen (HKSE:04332) has a Cyclically Adjusted FCF per Share of HK$95.53 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Amgen and its competitors.
Is Amgen's Cyclically Adjusted FCF per Share too high?
Amgen's current Cyclically Adjusted FCF per Share is HK$95.53. Overall, Amgen has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cyclically Adjusted FCF per Share compare to GILD and PFE?
Amgen's Cyclically Adjusted FCF per Share of HK$95.53 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Amgen and its competitors. Amgen's current Cyclically Adjusted FCF per Share is HK$95.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Amgen (HKSE:04332) has a current Cyclically Adjusted FCF per Share of HK$95.53. The stock's GF Value™ is HK$1,707.80, compared to a current price of HK$1,761.00 — trading 3.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is HK$95.53. Amgen's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Amgen (HKSE:04332), the current Cyclically Adjusted FCF per Share is HK$95.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (HKSE:04332) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of HK$1,761.00 is trading 3.1% above its estimated GF Value™ of HK$1,707.80.

Key valuation signals for HKSE:04332:

  • Cyclically Adjusted FCF per Share: HK$95.53
  • GF Value™: HK$1,707.80 vs. price of HK$1,761.00 (3.1% above fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the HKSE:04332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
86GF Score

Get the complete analysis for HKSE:04332

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1,761.00
Price
HK$1,707.80
GF Value